$CHRS
Coherus BioSciences, Inc. Stock $chrs

$chrs Overview Financials Valuation SEC Filings Company Website

2014 Form 10-K Financial Statement

#000156459015001896 Filed on March 23, 2015

Income Statement

Concept	2014	2013 Q4	2013 Q3
Revenue	$31.11M	$1.232M	$506.0K
YoY Change	1030.72%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$17.60M	$2.500M	$2.400M
YoY Change	134.67%
% of Gross Profit
Research & Development	$78.22M	$9.200M	$4.934M
YoY Change	150.08%
% of Gross Profit
Depreciation & Amortization	$674.0K	$100.0K	$101.0K
YoY Change	66.83%
% of Gross Profit
Operating Expenses	$95.79M	$11.72M	$7.289M
YoY Change	147.23%
Operating Profit	-$64.68M		-$6.783M
YoY Change	79.71%
Interest Expense	$3.900M	-$3.300M	$1.992M
YoY Change	-26.32%
% of Operating Profit
Other Income/Expense, Net	-$18.60M	-$800.0K	-$12.70M
YoY Change	50.58%
Pretax Income	-$87.20M	-$14.60M	-$21.50M
YoY Change	62.69%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$87.13M	-$14.60M	-$21.47M
YoY Change	62.46%
Net Earnings / Revenue	-280.12%	-1185.06%	-4243.68%
Basic Earnings Per Share
Diluted Earnings Per Share	-$10.62M	-$454.8K	-$669.8K
COMMON SHARES
Basic Shares Outstanding	8.520M		4.836M
Diluted Shares Outstanding

Balance Sheet

Concept	2014	2013 Q4	2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$150.4M	$39.60M
YoY Change	279.8%
Cash & Equivalents	$150.4M	$39.55M	$34.72M
Short-Term Investments
Other Short-Term Assets	$24.50M	$5.800M
YoY Change	322.41%
Inventory
Prepaid Expenses		$5.688M
Receivables		$278.0K
Other Receivables
Total Short-Term Assets	$179.1M	$45.68M
YoY Change	291.9%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.500M	$1.743M
YoY Change	164.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$100.0K	$27.00K
YoY Change
Total Long-Term Assets	$8.100M	$1.770M
YoY Change	376.47%
TOTAL ASSETS
Total Short-Term Assets	$179.1M	$45.68M
Total Long-Term Assets	$8.100M	$1.770M
Total Assets	$187.2M	$47.45M
YoY Change	294.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.800M	$3.302M
YoY Change	166.67%
Accrued Expenses	$11.20M	$7.300M
YoY Change	53.42%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due		$4.200M
YoY Change
Total Short-Term Liabilities	$51.80M	$53.70M
YoY Change	-3.54%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$68.70M	$61.00K
YoY Change	90.3%
Total Long-Term Liabilities	$68.70M	$61.00K
YoY Change	90.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$51.80M	$53.70M
Total Long-Term Liabilities	$68.70M	$61.00K
Total Liabilities	$120.4M	$89.83M
YoY Change	34.08%
SHAREHOLDERS EQUITY
Retained Earnings		-$99.59M
YoY Change
Common Stock		$2.515M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$66.80M	-$97.08M
YoY Change
Total Liabilities & Shareholders Equity	$187.2M	$47.45M
YoY Change	294.94%

Cashflow Statement

Concept	2014	2013 Q4	2013 Q3
OPERATING ACTIVITIES
Net Income	-$87.13M	-$14.60M	-$21.47M
YoY Change	62.46%
Depreciation, Depletion And Amortization	$674.0K	$100.0K	$101.0K
YoY Change	66.83%
Cash From Operating Activities	-$23.90M	$5.000M	$21.50M
YoY Change	-255.19%
INVESTING ACTIVITIES
Capital Expenditures	$2.849M	-$200.0K	$0.00
YoY Change	663.81%
Acquisitions
YoY Change
Other Investing Activities	$2.300M		$0.00
YoY Change
Cash From Investing Activities	-$500.0K	-$200.0K	$0.00
YoY Change	25.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$2.000K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	136.0M	0.000	10.00M
YoY Change	1260.0%
NET CHANGE
Cash From Operating Activities	-23.90M	5.000M	21.50M
Cash From Investing Activities	-500.0K	-200.0K	0.000
Cash From Financing Activities	136.0M	0.000	10.00M
Net Change In Cash	111.6M	4.800M	31.50M
YoY Change	346.4%
FREE CASH FLOW
Cash From Operating Activities	-$23.90M	$5.000M	$21.50M
Capital Expenditures	$2.849M	-$200.0K	$0.00
Free Cash Flow	-$26.75M	$5.200M	$21.50M
YoY Change	-278.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2014	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2014	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2417000
CY2014	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2015Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	33324459
CY2014Q2	dei	Entity Public Float EntityPublicFloat	0
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	150392000
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	50000
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1743000
CY2013Q4	us-gaap	Assets Current AssetsCurrent	45677000
CY2014Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	785000
CY2014Q4	us-gaap	Assets Current AssetsCurrent	179136000
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4472000
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	60000
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	3000
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	254048000
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2514000
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-525000
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-97077000
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	47447000
CY2014Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	1815000
CY2014Q4	chrs	Other Assets Current Related Parties OtherAssetsCurrentRelatedParties	1691000
CY2014	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2013Q4	us-gaap	Notes Receivable Related Parties Current NotesReceivableRelatedPartiesCurrent	107000
CY2013Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5688000
CY2013Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1111000
CY2013Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	3092000
CY2014Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	5710000
CY2013Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	24251000
CY2014Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	52000
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	21000
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	51783000
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	53701000
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	39899000
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	28567000
CY2013Q4	chrs	Collaboration Agreement Contingent Liability Noncurrent CollaborationAgreementContingentLiabilityNoncurrent	7500000
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	61000
CY2013Q4	us-gaap	Liabilities Liabilities	89829000
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-186725000
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	66801000
CY2014Q4	us-gaap	Minority Interest MinorityInterest	-44000
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4837715
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33257978
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4837715
CY2014	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	732000
CY2014	us-gaap	Sales Revenue Net SalesRevenueNet	31106000
CY2013	us-gaap	Sales Revenue Net SalesRevenueNet	2751000
CY2012	us-gaap	Sales Revenue Net SalesRevenueNet	1899000
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	78224000
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31279000
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17564000
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7465000
CY2014Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	20485000
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2276000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39554000
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	278000
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2620000
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-99592000
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33257978
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34886000
CY2012	us-gaap	Operating Expenses OperatingExpenses	40417000
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-38518000
CY2012	us-gaap	Interest Expense InterestExpense	1514000
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11117000
CY2014Q4	chrs	Collaboration Agreement Contingent Liability Noncurrent CollaborationAgreementContingentLiabilityNoncurrent	27650000
CY2011Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2307000
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5531000
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	19848000
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	34749000
CY2012	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	8101000
CY2014	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	1192000
CY2014	us-gaap	Operating Expenses OperatingExpenses	95788000
CY2013	us-gaap	Operating Expenses OperatingExpenses	38744000
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-35993000
CY2014	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-44000
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-87133000
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-53635000
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-10.64
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-16.10
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-15.85
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	8186529
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3332020
CY2012	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2082622
CY2014	chrs	Related Party Transaction Research And Development Expense RelatedPartyTransactionResearchAndDevelopmentExpense	21723000
CY2013	chrs	Related Party Transaction Research And Development Expense RelatedPartyTransactionResearchAndDevelopmentExpense	9471000
CY2012	chrs	Related Party Transaction Research And Development Expense RelatedPartyTransactionResearchAndDevelopmentExpense	16777000
CY2014	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	597000
CY2013	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	18000
CY2012	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	61000
CY2014	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	2687000
CY2013	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	4026000
CY2012	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	1059000
CY2014	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-525000
CY2012	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-33018000
CY2012	chrs	Adjustments To Additional Paid In Capital Convertible Debt With Beneficial Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithBeneficialConversionFeature	-10631000
CY2012	chrs	Adjustments To Additional Paid In Capital Vesting Of Restricted Stock Awards AdjustmentsToAdditionalPaidInCapitalVestingOfRestrictedStockAwards	10000
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	443000
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-45503000
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6000
CY2013	chrs	Adjustments To Additional Paid In Capital Vesting Of Restricted Stock Awards AdjustmentsToAdditionalPaidInCapitalVestingOfRestrictedStockAwards	10000
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2045000
CY2014	chrs	Adjustments To Additional Paid In Capital Convertible Debt With Beneficial Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithBeneficialConversionFeature	-3939000
CY2014	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	48000
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	55000
CY2014	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	2000
CY2014	chrs	Adjustments To Additional Paid In Capital Vesting Of Restricted Stock Awards AdjustmentsToAdditionalPaidInCapitalVestingOfRestrictedStockAwards	5000
CY2014	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	44000
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	674000
CY2013	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	404000
CY2012	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	221000
CY2014	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	5185000
CY2014	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	15899000
CY2013	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4557000
CY2012	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-639000
CY2013	chrs	Fair Value Of Warrants In Excess Of Debt Proceeds Recognized At Issuance FairValueOfWarrantsInExcessOfDebtProceedsRecognizedAtIssuance	3669000
CY2013	chrs	Fair Value Of Embedded Derivatives In Excess Of Debt Proceeds Recognized At Issuance FairValueOfEmbeddedDerivativesInExcessOfDebtProceedsRecognizedAtIssuance	4096000
CY2014	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	147000
CY2013	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	7579000
CY2012	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	7956000
CY2014	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3897000
CY2013	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	5293000
CY2012	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1514000
CY2014	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	2048000
CY2012	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	6369000
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	2045000
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2139000
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	120000
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	158000
CY2014	us-gaap	Increase Decrease In Notes Receivable Current IncreaseDecreaseInNotesReceivableCurrent	1815000
CY2014	us-gaap	Increase Decrease In Notes Receivable Related Parties Current IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent	-107000
CY2013	us-gaap	Increase Decrease In Notes Receivable Related Parties Current IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent	-16000
CY2012	us-gaap	Increase Decrease In Notes Receivable Related Parties Current IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent	5000
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	55000
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6000
CY2014	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2000
CY2014	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	14692000
CY2013	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	3284000
CY2012	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1999000
CY2014	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	2046000
CY2013	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-60000
CY2012	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	50000
CY2014	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-1691000
CY2014	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	25000
CY2013	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	21000
CY2012	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-207000
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3629000
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	924000
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	135956000
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	9956000
CY2012	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1685000
CY2014	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	1637000
CY2013	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-1310000
CY2012	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	1693000
CY2014	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3949000
CY2013	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2847000
CY2012	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2162000
CY2014	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	31000
CY2013	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-2000
CY2012	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	14000
CY2012	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	26938000
CY2013	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2900000
CY2013	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	7050000
CY2014	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	131000
CY2014	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	85419000
CY2014	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4307000
CY2013	chrs	Increase Decrease In Contingent Liability To Collaborator IncreaseDecreaseInContingentLiabilityToCollaborator	7500000
CY2012	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-9000
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-18251000
CY2014	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	2334000
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1783000
CY2014	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	10000
CY2012	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	40000
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1823000
CY2014	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	54660000
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	26938000
CY2014	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-666000
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	110838000
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	25006000
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6864000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14548000
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7684000
CY2014	chrs	Non Cash Contingent Consideration Related To Acquisition NonCashContingentConsiderationRelatedToAcquisition	1310000
CY2014	chrs	Convertible Preferred Stock Warrants Reclassified To Preferred Stock ConvertiblePreferredStockWarrantsReclassifiedToPreferredStock	40150000
CY2012	chrs	Convertible Preferred Stock Warrants Reclassified To Preferred Stock ConvertiblePreferredStockWarrantsReclassifiedToPreferredStock	400000
CY2014	chrs	Noncash Vesting Of Restricted Common Stock NoncashVestingOfRestrictedCommonStock	5000
CY2013	chrs	Noncash Vesting Of Restricted Common Stock NoncashVestingOfRestrictedCommonStock	10000
CY2012	chrs	Noncash Vesting Of Restricted Common Stock NoncashVestingOfRestrictedCommonStock	10000
CY2014	chrs	Purchase Of Equipment Included In Accounts Payable PurchaseOfEquipmentIncludedInAccountsPayable	726000
CY2013	chrs	Purchase Of Equipment Included In Accounts Payable PurchaseOfEquipmentIncludedInAccountsPayable	169000
CY2014	chrs	Initial Public Offering Costs Included In Accounts Payable InitialPublicOfferingCostsIncludedInAccountsPayable	855000
CY2014	chrs	Accrued Expenses Settled With Common Stock Warrants AccruedExpensesSettledWithCommonStockWarrants	55000
CY2014	chrs	Accrued Expenses Settled With Preferred Stock AccruedExpensesSettledWithPreferredStock	10000
CY2012	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	15535000
CY2012	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	10631000
CY2014	us-gaap	Nature Of Operations NatureOfOperations	<div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td> <td valign="top" style="width:95.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Organization and Operations </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description of the Business </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Coherus BioSciences, Inc. (the “Company”, “Coherus”, “we”, “our” or “us”) was incorporated in the state of Delaware as BioGenerics, Inc. in September 2010 and changed its name to Coherus BioSciences, Inc. in April 2012. The Company is a late-stage clinical biologics platform company, focused on the global biosimilar market. The Company’s headquarters and laboratories are located in Redwood City, California and in Camarillo, California, respectively. The Company operates in one segment. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s clinical stage pipeline consists of two anti-inflammatory agents targeting tumor necrosis factor, or TNF, and a long-acting form of granulocyte colony-stimulating factor, or G-CSF. The Company’s most clinically advanced anti-TNF product candidate, CHS-0214, is being developed as an etanercept (Enbrel) biosimilar that the Company has partnered with Baxter International Inc., Baxter Healthcare Corporation and Baxter Healthcare SA (collectively “Baxter”) and Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) to develop and commercialize in key markets outside of the United States. The Company is currently enrolling two Phase 3 clinical trials with CHS-0214 to support the planned filing of a marketing application in Europe in 2016. The Company’s second anti-TNF product candidate, CHS-1420, is being developed as an adalimumab (Humira) biosimilar. This product successfully completed a pivotal Phase 1 PK study in August 2014 by meeting the primary study endpoint. The Company plans to initiate a Phase 3 trial during the first half of 2015 to support the planned filing of a marketing application in the United States in 2016 and the European Union, or E.U., in 2017. The Company’s long-acting G-CSF product candidate, CHS-1701, is being developed as a pegfilgrastim (Neulasta) biosimilar. </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Initial Public Offering </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 6, 2014, the Company’s registration statement on Form S-1 (File No. 333-198936) relating to its initial public offering (“IPO”) of its common stock was declared effective by the Securities and Exchange Commission (“SEC”) and the shares began trading on The NASDAQ Global Market on November 6, 2014. The price of the shares sold in the IPO was $13.50 per share. The IPO closed on November 12, 2014, pursuant to which the Company sold 6,803,702 shares of common stock, including the sale of 507,402 shares of common stock to the underwriters upon their partial exercise of their over-allotment option. The Company received total gross proceeds from the offering of $91.8 million, after deducting underwriting discounts and commissions of $6.4 million and offering expenses of $5.2 million, the net proceeds were $80.2 million. In connection with the closing of the IPO, all shares of convertible preferred stock then outstanding converted into 21,316,519 shares of common stock, including 185,302 outstanding convertible preferred stock warrants were exercised, for cash or on a net basis. Also, all outstanding warrants for common stock were exercised, on a net basis, into 491,580 shares of common stock in connection with the IPO. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the effectiveness of the Amended and Restated Certificate of Incorporation of the Company on November 12, 2014, the number of shares of capital stock the Company is authorized to issue was increased to 300,000,000 shares of common stock and 5,000,000 shares of preferred stock. Both the common stock and preferred stock have a par value of $0.0001 per share. </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Need to Raise Additional Capital </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2014, the Company had an accumulated deficit of $186.7 million and cash and cash equivalents of $150.4 million. The Company believes that its current available cash and cash equivalents together with the cash received from the IPO, will be sufficient to fund its planned expenditures and meet the Company’s obligations through at least the next twelve months. However, if the anticipated operating results are not achieved in future periods, the planned expenditures may need to be reduced in order to extend the time period over which the then-available resources would be able to fund the operations. The Company will need to raise additional funds in the future, however there can be no assurance that such efforts will be successful or that, in the event that they are successful, the terms and conditions of such financing will be favorable<font style="font-weight:bold;">. </font></p></div>
CY2014	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its common stock valuation and related stock-based compensation, the valuations of the convertible preferred stock warrant liability and embedded derivative instruments, valuation of deferred tax assets, convertible preferred stock, clinical trial accruals, revenue recognition period, as well as certain accrued liabilities. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </p></div>
CY2014	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company’s financial instruments that are exposed to concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash in bank accounts which at times exceed federally insured limits. The Company attempts to minimize the<font style="font-family:inherit;"> risks related to cash and cash equivalents by investing in money markets with a broad and diverse range of financial instruments. The investment portfolio is maintained in accordance with the Company’s investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. </font>The Company also maintains restricted cash in money market funds that invest primarily in U.S. Treasury securities. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash and money market funds. </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Customer Concentration </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customers whose revenue accounted for 10% or more of total revenues were as follows: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="5" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="5" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2012</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Daiichi Sankyo - related party</p></td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100%</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Baxter</p></td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> </tr> </table></div> <p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:3pt;line-height:6pt;margin-top:0pt;margin-right:66.67%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:2.27%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></td> <td valign="top" style="width:97.73%;"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">less than 10% </p></td></tr></table></div></div>
CY2014	us-gaap	Preferred Stock Conversion Basis PreferredStockConversionBasis	In November 2014, as a result of the Company’s IPO, all shares of convertible preferred stock were converted into shares of common stock on a one-for-one basis.
CY2014	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	less than a 50%
CY2014	us-gaap	Derivatives Embedded Derivatives DerivativesEmbeddedDerivatives	<div> <p style="margin-top:18pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Embedded Derivative Liability </p> <p style="margin-top:6pt;line-height:11pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company recorded derivative instruments related to redemption features embedded within the convertible notes when such notes were outstanding. The embedded derivatives were accounted for as a liability and were remeasured to fair value as of each balance sheet date when such notes were outstanding, with the related remeasurement adjustment being recognized as a component of other income (expense), net in the consolidated statements of operations. </p></div>
CY2014Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2013Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2013Q3	us-gaap	Fair Value Inputs Discount Rate FairValueInputsDiscountRate	0.30
CY2014	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2014	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-1.667
CY2014	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	671000
CY2013	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-34000
CY2012	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0
CY2014	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2013Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0
CY2013Q3	us-gaap	Fair Value Inputs Discount Rate FairValueInputsDiscountRate	0.30
CY2013	chrs	Number Of Shares Underlying Warrants NumberOfSharesUnderlyingWarrants	4638644
CY2014	chrs	Net Change In Fair Value Of Convertible Preferred Stock Warrant Liability NetChangeInFairValueOfConvertiblePreferredStockWarrantLiability	15900000
CY2013	chrs	Net Change In Fair Value Of Convertible Preferred Stock Warrant Liability NetChangeInFairValueOfConvertiblePreferredStockWarrantLiability	8900000
CY2012	chrs	Net Change In Fair Value Of Convertible Preferred Stock Warrant Liability NetChangeInFairValueOfConvertiblePreferredStockWarrantLiability	-600000
CY2014Q1	chrs	Common Stock Warrant Fair Value Per Share CommonStockWarrantFairValuePerShare	5.73
CY2014Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	21316519
CY2014Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	1
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1922000
CY2013	us-gaap	Fair Value Inputs Discount Rate FairValueInputsDiscountRate	0.30
CY2013Q3	chrs	Fair Value Inputs New Equity Financing Percentage FairValueInputsNewEquityFinancingPercentage	0.25
CY2013Q3	chrs	Fair Value Inputs New Equity Financing Percentage FairValueInputsNewEquityFinancingPercentage	0.65
CY2013	chrs	Fair Value Inputs New Equity Financing Percentage FairValueInputsNewEquityFinancingPercentage	0.63
CY2013Q3	chrs	Fair Value Inputs New Equity Financing At Lower Valuation Then Previous Financing Percentage FairValueInputsNewEquityFinancingAtLowerValuationThenPreviousFinancingPercentage	0.05
CY2013Q3	chrs	Fair Value Inputs New Equity Financing At Lower Valuation Then Previous Financing Percentage FairValueInputsNewEquityFinancingAtLowerValuationThenPreviousFinancingPercentage	0.05
CY2013	chrs	Fair Value Inputs New Equity Financing At Lower Valuation Then Previous Financing Percentage FairValueInputsNewEquityFinancingAtLowerValuationThenPreviousFinancingPercentage	0.07
CY2013Q3	chrs	Fair Value Inputs Initial Public Offering Percentage FairValueInputsInitialPublicOfferingPercentage	0.05
CY2013Q3	chrs	Fair Value Inputs Initial Public Offering Percentage FairValueInputsInitialPublicOfferingPercentage	0.05
CY2013	chrs	Fair Value Inputs Initial Public Offering Percentage FairValueInputsInitialPublicOfferingPercentage	0.10
CY2013Q3	chrs	Fair Value Inputs Change Of Control Percentage FairValueInputsChangeOfControlPercentage	0.25
CY2013Q3	chrs	Fair Value Inputs Change Of Control Percentage FairValueInputsChangeOfControlPercentage	0.05
CY2013Q3	chrs	Fair Value Inputs Maturity Percentage FairValueInputsMaturityPercentage	0.40
CY2013Q3	chrs	Fair Value Inputs Maturity Percentage FairValueInputsMaturityPercentage	0.20
CY2013	chrs	Fair Value Inputs Maturity Percentage FairValueInputsMaturityPercentage	0.20
CY2013Q4	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	0
CY2012Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Net EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet	0
CY2013	us-gaap	Embedded Derivative Loss On Embedded Derivative EmbeddedDerivativeLossOnEmbeddedDerivative	4096000
CY2013Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Net EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet	0
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2368000
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	625000
CY2014Q4	us-gaap	Accrued Utilities Current AccruedUtilitiesCurrent	2997000
CY2013Q4	us-gaap	Accrued Utilities Current AccruedUtilitiesCurrent	2792000
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1549000
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	252000
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	995000
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4547000
CY2014	us-gaap	License And Services Revenue LicenseAndServicesRevenue	30374000
CY2013	us-gaap	License And Services Revenue LicenseAndServicesRevenue	2751000
CY2012	us-gaap	License And Services Revenue LicenseAndServicesRevenue	1899000
CY2014Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	2335000
CY2014Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets	107000
CY2014Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities	1027000
CY2014Q4	chrs	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment	2620000
CY2014Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	4978000
CY2014Q4	chrs	Number Of Contingent Consideration For Potential Payments NumberOfContingentConsiderationForPotentialPayments	2
CY2014	chrs	Contingent Consideration Probability Of Completion ContingentConsiderationProbabilityOfCompletion	0.75
CY2014	chrs	Fair Value Inputs Contingent Probability FairValueInputsContingentProbability	0.075
CY2014Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	6500000
	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	0
CY2013Q4	chrs	Conversion Cash Payment Percentage ConversionCashPaymentPercentage	1.00
CY2013Q4	chrs	Reduced Derivative Liability ReducedDerivativeLiability	0
CY2013	us-gaap	Interest Expense Debt InterestExpenseDebt	4800000
CY2014	us-gaap	Interest Expense Debt InterestExpenseDebt	3900000
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1082000
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1117000
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	404000
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2603000
CY2012	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	371000
CY2013	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	428000
CY2014	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	763000
CY2014	us-gaap	Litigation Settlement Amount LitigationSettlementAmount	0
CY2014Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0
CY2013Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	28090997
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	853244
CY2013	chrs	Share Based Compensation Arrangement By Share Based Payment Award Options Below Fair Value Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBelowFairValueGrantsInPeriod	786018
CY2013	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	3248
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	123713
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3047396
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	614062
CY2014	chrs	Share Based Compensation Arrangement By Share Based Payment Award Options Below Fair Value Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBelowFairValueGrantsInPeriod	2703441
CY2014	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	48414
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	546178
CY2013Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	9153906
CY2013Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	9153906
CY2013Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	54695000
CY2013Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	58282000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	14999
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	1520830
CY2012	chrs	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Granted At Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAtFairValue	611285
CY2012	chrs	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Forfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesForfeited	28680
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	953224
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	1586570
CY2013	chrs	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Granted At Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAtFairValue	853244
CY2013	chrs	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Granted Below Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedBelowFairValue	786018
CY2013	chrs	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Forfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesForfeited	123713
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1024245
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	4399580
CY2014	chrs	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Granted At Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAtFairValue	614062
CY2014	chrs	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Granted Below Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedBelowFairValue	2703441
CY2014	chrs	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Forfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesForfeited	546178
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2652500
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	611285
CY2012	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	22307
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	28680
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1535095
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5770307
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.358
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.084
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.008
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.008
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.057
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.084
CY2013	chrs	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Below Fair Value Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodBelowFairValueWeightedAverageExercisePrice	1.417
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.084
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.271
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.427
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	13.907
CY2014	chrs	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Below Fair Value Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodBelowFairValueWeightedAverageExercisePrice	1.833
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.144
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.831
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.909
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5770307
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5764337
CY2014Q4	chrs	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber	2364401
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2365651
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.909
CY2014Q4	chrs	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice	1.483
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.482
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y7M24D
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y7M21D
CY2014	chrs	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm	P8Y5M27D
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y10M24D
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	77383000
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	77303000
CY2014Q4	chrs	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAggregateIntrinsicValue	35080000
CY2014Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	35101000
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y6M
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M4D
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y15D
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.99
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.08
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.10
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0205
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0123
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0093
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	4200000
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	700000
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	95000
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.65
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.88
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.73
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	391000
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	46000
CY2014Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	18500000
CY2014	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y3M11D
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3400
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3400
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3400
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0165
CY2013	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0397
CY2012	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0668
CY2014	chrs	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.1080
CY2013	chrs	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.1240
CY2012	chrs	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.0565
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0311
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0453
CY2014	chrs	Effective Income Tax Rate Reconciliation Net Operating Loss EffectiveIncomeTaxRateReconciliationNetOperatingLoss	0.0001
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Investment EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment	0.0073
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0002
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0017
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2542
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.3010
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.4616
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00
CY2012	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	34463000
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	27524000
CY2014Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	6032000
CY2013Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2823000
CY2014Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	854000
CY2013Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	26000
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1428000
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	82000
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	940000
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	626000
CY2014Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	12762000
CY2013Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	2413000
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	56479000
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	33494000
CY2014Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	892000
CY2014Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	892000
CY2014Q4	chrs	Deferred Tax Asset Liability Net DeferredTaxAssetLiabilityNet	55587000
CY2013Q4	chrs	Deferred Tax Asset Liability Net DeferredTaxAssetLiabilityNet	33494000
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	55587000
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	33494000
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2013Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2014	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	22100000
CY2013	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	16100000
CY2014Q4	chrs	Operating Loss Carryforward Future Equity Effect Of Unrecognized Tax Benefits From Stock Options Exercised OperatingLossCarryforwardFutureEquityEffectOfUnrecognizedTaxBenefitsFromStockOptionsExercised	1600000
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	749000
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	73000
CY2011Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	14000
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	861000
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	319000
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	59000
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	2206000
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	357000
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3816000
CY2014	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2013	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2012	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8520100
CY2013	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4828214
CY2012	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4963883
CY2014	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	333571
CY2013	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	1496194
CY2012	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	2881261
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5770307
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16839946
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11048025
CY2011Q4	us-gaap	Notes Receivable Related Parties Current NotesReceivableRelatedPartiesCurrent	133000
CY2014Q1	us-gaap	Sales Revenue Net SalesRevenueNet	3596000
CY2014Q2	us-gaap	Sales Revenue Net SalesRevenueNet	4965000
CY2014Q3	us-gaap	Sales Revenue Net SalesRevenueNet	16052000
CY2014Q4	us-gaap	Sales Revenue Net SalesRevenueNet	6493000
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	17357000
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	22903000
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	22475000
CY2014Q4	us-gaap	Operating Expenses OperatingExpenses	33053000
CY2014Q1	us-gaap	Profit Loss ProfitLoss	-25170000
CY2014Q2	us-gaap	Profit Loss ProfitLoss	-25070000
CY2014Q3	us-gaap	Profit Loss ProfitLoss	-7914000
CY2014Q4	us-gaap	Profit Loss ProfitLoss	-29023000
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-25170000
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-24957000
CY2013Q4	us-gaap	Operating Expenses OperatingExpenses	11719000
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-8862000
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.14
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.80
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-6.23
CY2013Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.68
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-7872000
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	-29134000
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-6.04
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.96
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.79
CY2014Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.47
CY2013Q1	us-gaap	Sales Revenue Net SalesRevenueNet	506000
CY2013Q2	us-gaap	Sales Revenue Net SalesRevenueNet	507000
CY2013Q3	us-gaap	Sales Revenue Net SalesRevenueNet	506000
CY2013Q4	us-gaap	Sales Revenue Net SalesRevenueNet	1232000
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	9945000
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	9791000
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	7289000

Files In Submission

Name	View Source	Status
0001564590-15-001896-index-headers.html	Edgar Link	pending
0001564590-15-001896-index.html	Edgar Link	pending
0001564590-15-001896.txt	Edgar Link	pending
0001564590-15-001896-xbrl.zip	Edgar Link	pending
chrs-10k_20141231.htm	Edgar Link	pending
chrs-20141231.xml	Edgar Link	completed
chrs-20141231.xsd	Edgar Link	pending
chrs-20141231_cal.xml	Edgar Link	unprocessable
chrs-20141231_def.xml	Edgar Link	unprocessable
chrs-20141231_lab.xml	Edgar Link	unprocessable
chrs-20141231_pre.xml	Edgar Link	unprocessable
chrs-ex231_2014123115.htm	Edgar Link	pending
chrs-ex311_2014123114.htm	Edgar Link	pending
chrs-ex312_2014123113.htm	Edgar Link	pending
chrs-ex321_2014123112.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
g20150323195201518160.jpg	Edgar Link	pending
g20150323195202347161.jpg	Edgar Link	pending
g20150323195202972162.jpg	Edgar Link	pending
g20150323195220847163.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CHRS
Coherus BioSciences, Inc. Stock $chrs

2014 Form 10-K Financial Statement

#000156459015001896 Filed on March 23, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CHRS Coherus BioSciences, Inc. Stock $chrs

2014 Form 10-K Financial Statement

#000156459015001896 Filed on March 23, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CHRS
Coherus BioSciences, Inc. Stock $chrs